304 related articles for article (PubMed ID: 28624108)
81. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation.
Korucu B; Yeter H; Guz G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Apr; 43(1):101-107. PubMed ID: 35451298
[No Abstract] [Full Text] [Related]
82. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
[TBL] [Abstract][Full Text] [Related]
83. Safety and efficacy of everolimus initiation from the first month after liver transplantation: A systematic review and meta-analysis.
Cholongitas E; Burra P; Vourli G; Papatheodoridis GV
Clin Transplant; 2023 May; 37(5):e14957. PubMed ID: 36880482
[TBL] [Abstract][Full Text] [Related]
84. Adverse effects of immunosuppression after liver transplantation.
Noble J; Terrec F; Malvezzi P; Rostaing L
Best Pract Res Clin Gastroenterol; 2021; 54-55():101762. PubMed ID: 34874845
[TBL] [Abstract][Full Text] [Related]
85. Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT).
Cillo U; Carraro A; Avolio AW; Cescon M; Di Benedetto F; Giannelli V; Magistri P; Nicolini D; Vivarelli M; Lanari J;
Updates Surg; 2024 Jun; 76(3):725-741. PubMed ID: 38713396
[TBL] [Abstract][Full Text] [Related]
86. Does mtori base immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? Systematic review and meta-analysis of randomized controlled trials.
ALoun A; Abu-Zeid EED; Garzali IU
Hepatol Forum; 2023 Mar; 4(2):82-88. PubMed ID: 37250931
[TBL] [Abstract][Full Text] [Related]
87. Impact of immunosuppressive therapy on brain derived cytokines after liver transplantation.
Dirks M; Pflugrad H; Tryc AB; Schrader AK; Ding X; Lanfermann H; Jäckel E; Schrem H; Beneke J; Barg-Hock H; Klempnauer J; Falk CS; Weissenborn K
Transpl Immunol; 2020 Feb; 58():101248. PubMed ID: 31669260
[TBL] [Abstract][Full Text] [Related]
88. Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial.
Solberg OG; Stavem K; Ragnarsson A; Ioanes D; Arora S; Endresen K; Benth JŠ; Gullestad L; Gude E; Andreassen AK; Aaberge L
J Heart Lung Transplant; 2016 Aug; 35(8):1010-7. PubMed ID: 27113960
[TBL] [Abstract][Full Text] [Related]
89. Five-year Outcome of an Early Everolimus-based Quadruple Immunosuppression in Lung Transplant Recipients: Follow-up of the 4EVERLUNG Study.
Kneidinger N; Valtin C; Hettich I; Frye BC; Wald A; Wilkens H; Bessa V; Gottlieb J
Transplantation; 2022 Sep; 106(9):1867-1874. PubMed ID: 35283454
[TBL] [Abstract][Full Text] [Related]
90. Immunosuppression in liver transplantation.
Mukherjee S; Botha JF; Mukherjee U
Curr Drug Targets; 2009 Jun; 10(6):557-74. PubMed ID: 19519358
[TBL] [Abstract][Full Text] [Related]
91. Real life experience with mTOR-inhibitors after lung transplantation.
Bos S; De Sadeleer LJ; Yserbyt J; Dupont LJ; Godinas L; Verleden GM; Ceulemans LJ; Vanaudenaerde BM; Vos R
Int Immunopharmacol; 2021 May; 94():107501. PubMed ID: 33647822
[TBL] [Abstract][Full Text] [Related]
92. Immunosuppression in Liver Transplantation: State of the Art and Future Perspectives.
Nedredal GI; Picon RV; Chedid MF; Foss A
Curr Pharm Des; 2020; 26(28):3389-3401. PubMed ID: 32520679
[TBL] [Abstract][Full Text] [Related]
93. Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art.
Zorzetti N; Lauro A; Khouzam S; Marino IR
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):3-9. PubMed ID: 35384800
[TBL] [Abstract][Full Text] [Related]
94. Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.
Karolin A; Genitsch V; Sidler D
Pharmacology; 2021; 106(7-8):347-355. PubMed ID: 34130291
[TBL] [Abstract][Full Text] [Related]
95. The role of antibody induction in liver transplantation.
Eason JD
Curr Opin Organ Transplant; 2007 Jun; 12(3):242-244. PubMed ID: 27711011
[TBL] [Abstract][Full Text] [Related]
96. Use of everolimus in liver transplantation: The French experience.
Dumortier J; Dharancy S; Calmus Y; Duvoux C; Durand F; Salamé E; Saliba F
Transplant Rev (Orlando); 2016 Jul; 30(3):161-70. PubMed ID: 27083870
[TBL] [Abstract][Full Text] [Related]
97. Current strategies for immunosuppression following liver transplantation.
Gotthardt DN; Bruns H; Weiss KH; Schemmer P
Langenbecks Arch Surg; 2014 Dec; 399(8):981-8. PubMed ID: 24748543
[TBL] [Abstract][Full Text] [Related]
98. Management of long-term complications from immunosuppression.
Russo MW; Wheless W; Vrochides D
Liver Transpl; 2024 Jun; 30(6):647-658. PubMed ID: 38315054
[TBL] [Abstract][Full Text] [Related]
99. Immunosuppression for older liver transplant recipients.
De Simone P; Battistella S; Lai Q; Ducci J; D'Arcangelo F; Marchetti P; Russo FP; Burra P
Transplant Rev (Orlando); 2024 Jan; 38(1):100817. PubMed ID: 38128152
[TBL] [Abstract][Full Text] [Related]
100. Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma.
Kang SH; Hwang S; Ha TY; Song GW; Jung DH; Kim KH; Ahn CS; Moon DB; Park GC; Jung BH; Yoon YI; Lee SG
Korean J Hepatobiliary Pancreat Surg; 2014 May; 18(2):48-51. PubMed ID: 26155248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
